Importantly, given that DNAJB9 and FBXO45 are tightly correlated in patients with breast cancer, our findings highlight DNAJB9 as a potential biomarker for predicting patient survival and a novel therapeutic target for treating patients with breast cancer. This evidence concerns the gene DNAJB9 and breast cancer.